Erythropoietin Drugs Market

Erythropoietin Drugs Market Size:

The global erythropoietin drugs market size reached USD 11.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 17.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032. The market growth is primarily driven by the increasing occurrence of chronic diseases, ongoing developments in drug development, including long-acting formulations, and the rising adoption of biosimilars offering cost-effective alternatives, enhancing accessibility, and supporting expansion.

Erythropoietin (EPO) drugs comprise various drugs, such as epoetin-alfa, epoetin-beta, and darbepoetin-alfa, that are consumed to cure EPO deficiency in the body. They are manufactured synthetically using recombinant deoxyribonucleic acid (DNA) technology. They stimulate the production of red blood cells (RBCs) in bone marrow and regulate the concentration of hemoglobin in the body. They assist in enhancing endurance, reducing tiredness, increasing metabolism, and improving the healing process of muscles while maintaining a healthy amount of erythrocytes in the body. They are utilized to treat various diseases, such as anemia, end-stage renal disease, human immunodeficiency virus (HIV), and hematology, among individuals. Besides this, EPO drugs are consumed by athletes to enhance their performance and aerobic capacity, as they benefit in increasing the availability of oxygen to their muscles.

Erythropoietin Drugs Market Trends:

Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, such as cancer and kidney disorders, are driving the demand for erythropoietin drugs. These conditions often lead to anemia, where erythropoietin therapy becomes essential in managing low red blood cell levels. The rise in global cancer cases, particularly in older patients, further propels the need for supportive treatments such as erythropoietin to alleviate chemotherapy-induced anemia. An NCBI article notes that gastrointestinal (42.1%) and breast (17.9%) cancers were most common, with 56.8% of patients in advanced stages. Anemia was present in 50.5%, especially in colorectal and genitourinary cancers. The average hemoglobin drop was 9.1 g/dL, with 79% of patients requiring transfusions. Severity of anemia was linked to older age, more chemotherapy cycles, and chronic disease, particularly in those 65 and older. Additionally, the growing incidences of chronic kidney disease (CKD) has significantly contributed to the market expansion, as erythropoietin drugs remain crucial in addressing anemia associated with CKD.

Continual Advancements in Drug Development

Ongoing advancements in biopharmaceutical research are driving the development of next-generation erythropoietin drugs, significantly enhancing both efficacy and patient outcomes. The introduction of long-acting erythropoietin formulations, which reduce the frequency of dosing and improve patient compliance by offering more convenient treatment schedules, is one such key innovation. In addition to this, biotech companies are focusing on creating biosimilars and novel erythropoiesis-stimulating agents (ESAs) that are designed to have fewer side effects, addressing safety concerns. These innovations not only offer improved therapeutic options but also provide more competitive pricing, making them accessible in regions with limited healthcare budgets, further meeting the erythropoietin drugs market demand and supporting the expansion globally.

Growing Adoption of Biosimilars

The market is experiencing a rise in the adoption of biosimilars, driven by increasing cost pressures in healthcare and the expiration of patents for original biologics. Biosimilars offer a more affordable alternative without compromising on efficacy or safety, making them a popular choice in both developed and emerging markets. Governments and healthcare systems are actively promoting the use of biosimilars to reduce treatment costs, particularly in regions with limited healthcare resources. This trend is significantly augmenting the erythropoietin drugs market share as more biotech companies focus on developing and launching erythropoietin biosimilars, further expanding access to these essential therapies globally.

Erythropoietin Drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global erythropoietin drugs market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on drug class, product type, application, and end user.

Drug Class Insights:

• Biologics
• Biosimilars
   

The report has provided a detailed breakup and analysis of the erythropoietin drugs market based on the drug class. This includes biologics and biosimilars. According to the report, biologics represented the largest segment.

Product Type Insights:

• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa
• Others
   

A detailed breakup and analysis of the erythropoietin drugs market based on the product type has also been provided in the report. This includes epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. According to the report, epoetin-alfa accounted for the largest market share.

Application Insights:

• Hematology
• Kidney Disorder
• Cancer
• Others
   

A detailed breakup and analysis of the erythropoietin drugs market based on the application has also been provided in the report. This includes hematology, kidney disorder, cancer, and others. According to the report, kidney disorder accounted for the largest market share.

End-User Insights:

• Hospitals
• Homecare
• Specialty Clinics
• Others
   

A detailed breakup and analysis of the erythropoietin drugs market based on the end-user has also been provided in the report. This includes hospitals, homecare, specialty clinics, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for erythropoietin drugs. Some of the factors driving the North America erythropoietin drugs market included the increasing approvals of erythropoietin drugs, various incentives offered by governing agencies for research on chronic diseases, rising prevalence of cancer among individuals, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global erythropoietin drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

• Amgen Inc.
• Biocon Limited
• Dr. Reddy’s Laboratories Ltd.
• F. Hoffmann-La Roche AG
• Intas Pharmaceuticals Ltd.
• Johnson & Johnson
• LG Chem Ltd.
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.
   

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Erythropoietin Drugs Market News:

• October 23, 2023: Genexine and PT Kalbe Genexine Biologics have received approval from the Indonesian Ministry of Food and Drug Safety for their long-acting erythropoietin, Efepoetin alfa (GX-E4), to treat chronic kidney disease-induced anemia in non-dialysis patients. This marks the first market approval for a drug resulting from Genexine's collaboration with KGbio. While the approval is currently for non-dialysis patients, further approvals for dialysis patients are expected in the future.

Erythropoietin Drugs Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the erythropoietin drugs market from 2018-2032.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global erythropoietin drugs market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the erythropoietin drugs industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.